Researchers pinpoint enzyme involved in arthritis onset

November 11, 2003

Researchers from Cardiff University have uncovered a molecular pathway that plays a pivotal role in the onset of arthritis. Their research, published this week in Arthritis Research & Therapy, could aid in the discovery of novel targets for arthritis drugs.

The researchers found that inhibiting the enzyme PKR could prevent two processes central to the onset of arthritis: the production and activation of enzymes that break down connective tissue; and the release from cartilage of one of its principal constituents, proteoglycan.

They said: "Collectively these results support our hypothesis that PKR is implicated in the cartilage degradation that occurs in arthritic disease."

Despite the differences between osteoarthritis and rheumatoid arthritis, it is likely that similar molecular pathways can cause the degradation of cartilage in both diseases. Cartilage degradation results from an imbalance of enzymes that break down connective tissue and their inhibitors. In particular, activity levels of the enzymes MMP-2 and MMP-9 are frequently increased in the cartilage of people suffering from osteoarthritis.

The research team, led by Dr Sophie Gilbert, cultured cartilage cells in vitro. They then stimulated the cells with two molecules, TNF-a and C2-ceramide. The molecules simulated arthritic processes, increasing the release of proteoglycan and the production and activation of MMPs.

The researchers then repeated the experiment, but inhibited PKR at the same time. This time they found that there was no increase in the activation of MMP-2 or MMP-9 and that the release of proteoglycan was significantly reduced.

Their results imply that PKR is involved in the molecular pathways, stimulated by TNF-a and C2-ceramide, that are implicated in the progression of arthritis, since the simulation of arthritis was prevented by inhibiting PKR.

Arthritis is a common problem worldwide. Both osteoarthritis and rheumatoid arthritis cause joint pain and stiffness, which can result in severe pain and disability. Osteoarthritis is the most common form of the disease, affecting more than 2 million Britons and 20 million Americans.

As yet there is no cure for arthritis, and no effective treatments to repair damaged cartilage. The researchers hope that, through understanding more about the molecular pathway in which PKR is involved, they will be able to discover new drug targets for the treatment of arthritis.
-end-
This release is based on the following article:

Does protein kinase R mediate TNF-a- and ceramide-induced increases in expression and activation of matrix metalloproteinases in articular cartilage by a novel mechanism?
Sophie J Gilbert, Victor C Duance and Deborah J Mason
Arthritis Res Ther 2004, 6:R46-R55
Published 12 November 2003

Upon publication this article will be available online at http://arthritis-research.com/content/6/1/R46, without barrier to access, as per Arthritis Research & Therapy's open access policy. Please publish the URL in any article you write, so your readers can read the full study.

For further information about this research, please contact Sophie Gilbert by email at GilbertSJ1@Cardiff.ac.uk

Alternatively, or for further information about the journal or open access, please contact Gemma Bradley, by email at press@biomedcentral.com or by phone on 207-323-0323 x2331

Arthritis Research & Therapy (http://www.arthritis-research.com) is published by BioMed Central (http://www.biomedcentral.com), an independent online publishing house committed to providing immediate free access to the peer-reviewed biological and medical research. This commitment is based on the view that open access to research is essential to the rapid and efficient communication of science. In addition to open-access original research, BioMed Central also publishes reviews and other subscription-based content.

BioMed Central

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.